Recent advances in development of CDK7 inhibitors and their clinical trials: a narrative review.

ABSTRACT:

Background and objective

CDK7, a member of the CDK-activating kinase (CAK) family, plays a key role in cell cycle, transcriptional regulation and in regulating the proliferation and apoptosis of tumor cells. Some evidence suggests that CDK7 is a promising target for cancer treatments, so it is of great significance to develop an efficient and highly selective CDK7 inhibitor. CDK7 inhibitors have not yet been marketed. This review focuses on some selective CDK7 inhibitors currently in clinical research, and introduces their targets, indications, and the latest clinical trial progress in detail.

Methods

We investigated the recent advances in development of CDK7 inhibitors and their clinical trials from online website (Google Scholar, ClinicalTrials.gov) and electronic database

SUBMITTER: Zhang L 

PROVIDER: S-EPMC12554479 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature